Ulodesine, also known as BCX4208, is a purine nucleoside phosphorylase (PNP) inhibitor in development as a once-daily oral, chronic treatment for gout. Ulodesine is currently being developed by Biocryst. Ulodesine acts upstream of xanthine oxidase in the purine metabolism pathway to reduce the production of serum uric acid (sUA). Ulodesine has an IC(50) of 0.5 nM to PNP. BCX-4208 is currently undergoing early clinical investigation in psoriasis and gout.
MedKoo Cat#: 206081
Name: Ulodesine
CAS#: 548486-59-5 (free base)
Chemical Formula: C12H16N4O3
Exact Mass: 264.1222
Molecular Weight: 264.28
Elemental Analysis: C, 54.54; H, 6.10; N, 21.20; O, 18.16
The following data is based on the product molecular weight 264.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
